The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Galactomannan and Computed Tomography-Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study
Abstract
BACKGROUND: Empirical antifungal therapy is the standard treatment for persistent or relapsing antibiotic-resistant neutropenic fever. However, overtreatment resulting in increased toxicity and treatment-related cost is a major shortcoming of such therapy. We assessed the feasibility of a "preemptive" approach based on the incorporation of sensitive, noninvasive diagnostic tests for consecutive high-risk neutropenic patients who had received fluconazole prophylaxis while avoiding empirical therapy. METHODS: A total of 136 treatment episodes for persons who were at risk of acquiring invasive fungal infection (IFI) were screened for the presence of galactomannan with an enzyme immunoassay. A diagnostic evaluation, which included thoracic computed tomography scanning (HRCT) and bronchoscopy with lavage, was performed on the basis of well-defined clinical, radiological, and microbiological criteria. Only seropositive patients and patients with a positive microbiological test result plus supportive radiological findings received liposomal amphotericin B. RESULTS: Neutropenic fever developed in 117 episodes, of which at least 41 episodes (35%) satisfied existing criteria for empirical antifungal therapy. However, our protocol-driven preemptive approach reduced the rate of antifungal use for these episodes from 35% to 7.7% (a 78% reduction) and led to the early initiation of antifungal therapy in 10 episodes (7.3%) that were clinically not suspected of being IFI. No undetected cases of invasive aspergillosis were identified; 1 case of zygomycosis was missed. Breakthrough candidemia was diagnosed by conventional culture techniques and was treated successfully. With use of a preemptive approach, the 12-week survival rate for patients with IFI was 63.6% (it was 63.1% for those with invasive aspergillosis). CONCLUSION: Preemptive therapy based on enzyme immunoassay and HRCT reduced the exposure to expensive and potentially toxic drugs and offered effective antifungal control, but it failed to detect non-Aspergillus IFI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Self-citationThe World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Denning, D. W. (1998) · Clinical Infectious Diseases · doi:10.1086/513943 · Cited by 1,492
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
Walsh, T. J., Teppler, H., Donowitz, G. R., Maertens, J. A., Baden, L. R., Dmoszynska, A., Cornely, O. A., Bourque, M. R., Lupinacci, R. J., Sable, C. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040446 · Cited by 919
Self-citationPizzo, P. A., Robichaud, K. J., Gill, F. A., & Witebsky, F. G. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90594-0 · Cited by 859
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Caillot, D., Casasnovas, O., Bernard, A., Couaillier, J. F., Durand, C., Cuisenier, B., Solary, E., Piard, F., Petrella, T., Bonnin, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.139 · Cited by 706
Odabasi, Z., Mattiuzzi, G., Estey, E., Kantarjian, H., Saeki, F., Ridge, R. J., Ketchum, P. A., Finkelman, M. A., Rex, J. H., & Ostrosky-Zeichner, L. (2004) · Clinical Infectious Diseases · doi:10.1086/421944 · Cited by 642
Caillot, D., Couaillier, J.-F., Bernard, A., Casasnovas, O., Denning, D. W., Mannone, L., Lopez, J., Couillault, G., Piard, F., Vagner, O., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.1.253 · Cited by 587
Maertens, J., Verhaegen, J., Lagrou, K., Van Eldere, J., & Boogaerts, M. (2001) · Blood · doi:10.1182/blood.v97.6.1604 · Cited by 513
Self-citationMarr, K. A., Balajee, S. A., McLaughlin, L., Tabouret, M., Bentsen, C., & Walsh, T. J. (2004) · The Journal of Infectious Diseases · doi:10.1086/422009 · Cited by 483
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis
Mennink-Kersten, M. A., Donnelly, J. P., & Verweij, P. E. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01045-x · Cited by 482
Prentice, H. G., Hann, I. M., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., Pinkerton, C. R., Schey, S. A., Jacobs, F., Oakhill, A., et al. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.2473063.x · Cited by 439
Aspergillus Galactomannan Detection in the Diagnosis of Invasive Aspergillosis in Cancer Patients
Herbrecht, R., Letscher-Bru, V., Oprea, C., Lioure, B., Waller, J., Campos, F., Villard, O., Liu, K.-L., Natarajan-Amé, S., Lutz, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.004 · Cited by 392
Empiric antifungal therapy in febrile granulocytopenic patients
(1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90441-5 · Cited by 378
Maertens, J., Van Eldere, J., Verhaegen, J., Verbeken, E., Verschakelen, J., & Boogaerts, M. (2002) · The Journal of Infectious Diseases · doi:10.1086/343804 · Cited by 343
Self-citationHusain, S., Alexander, B. D., Munoz, P., Avery, R. K., Houston, S., Pruett, T., Jacobs, R., Dominguez, E. A., Tollemar, J. G., Baumgarten, K., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375822 · Cited by 337
Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00010 · Cited by 321
Self-citationKawazu, M., Kanda, Y., Nannya, Y., Aoki, K., Kurokawa, M., Chiba, S., Motokura, T., Hirai, H., & Ogawa, S. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2733-2741.2004 · Cited by 280
Empirical antifungal therapy in febrile granulocytopenic patients
Meunier, F. (1989) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 268
Antimicrobial therapy of unexplained fever in neutropenic patients
Link, H., B�hme, A., Cornely, O. A., H�ffken, K., Kellner, O., Kern, W. V., Mahlberg, R., Maschmeyer, G., Nowrousian, M. R., Ostermann, H., et al. (2003) · Annals of Hematology · doi:10.1007/s00277-003-0764-4 · Cited by 251
Sulahian, A., Touratier, S., & Ribaud, P. (2003) · New England Journal of Medicine · doi:10.1056/nejm200312113492424 · Cited by 237
Sulahian, A., Boutboul, F., Ribaud, P., Leblanc, T., Lacroix, C., & Derouin, F. (2001) · Cancer · doi:10.1002/1097-0142(20010115)91:2<311::aid-cncr1003>3.0.co;2-3 · Cited by 226
Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan
Swanink, C. M., Meis, J. F., Rijs, A. J., Donnelly, J. P., & Verweij, P. E. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.1.257-260.1997 · Cited by 222
Towards a targeted, risk‐based, antifungal strategy in neutropenic patients
Prentice, H. G., Kibbler, C. C., & Prentice, A. G. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02014.x · Cited by 181
Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.857-869.2001 · Cited by 179
Boutboul, F., Alberti, C., Leblanc, T., Sulahian, A., Gluckman, E., Derouin, F., & Ribaud, P. (2002) · Clinical Infectious Diseases · doi:10.1086/339324 · Cited by 179
Maertens, J., Theunissen, K., Verbeken, E., Lagrou, K., Verhaegen, J., Boogaerts, M., & Eldere, J. V. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05140.x · Cited by 169
Self-citationCometta, A., Kern, W. V., De Bock, R., Paesmans, M., Vandenbergh, M., Crokaert, F., Engelhard, D., Marchetti, O., Akan, H., Skoutelis, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376637 · Cited by 168
Practice Guidelines for Evaluating New Fever in Critically Ill Adult Patients
O’Grady, N. P., Barie, P. S., Bartlett, J. G., Bleck, T. P., Garvey, G. J., Jacobi, J., Linden, P., Maki, D. G., Nam, M., Pasculle, W. A., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/520308 · Cited by 147
Hebart, H. F., Löffler, J., Reitze, H., Engel, A., Schumacher, U., Klingebiel, T., Bader, P., Böhme, A., Martin, H., Bunjes, D. W., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02378.x · Cited by 127
Verweij, P. E., Meis, J. F. G. M., Dompeling, E., Donnelly, J. P., & Schattenberg, A. (1997) · Infection · doi:10.1007/bf02113581 · Cited by 79
Prevention of fungal infections in the immunocompromised host.
Mahfouz, T. H., & Anaissie, E. J. (2003) · PubMed · Cited by 74
Antifungal Therapy in Patients with Fever and Neutropenia — More Rational and Less Empirical?
Klastersky, J. A. (2004) · New England Journal of Medicine · doi:10.1056/nejme048203 · Cited by 69
Fungal Infections in Patients With Neutropenia: Challenges in Prophylaxis and Treatment
Herbrecht, R., Neuville, S., Letscher‐Bru, V., Natarajan‐Amé, S., & Lortholary, O. (2000) · Drugs & Aging · doi:10.2165/00002512-200017050-00002 · Cited by 35
Invasive aspergillosis: current and future challenges in diagnosis and therapy
Hope, W. W., & Denning, D. W. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00809.x · Cited by 35
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citation
Metadata
- Authors
- Maertens, J., Theunissen, K., Verhoef, G., Verschakelen, J., Lagrou, K., Verbeken, E., Wilmer, A., Verhaegen, J., Boogaerts, M., & Eldere, J. V.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-01
- Volume
- 41
- Issue
- 9
- Pages
- 1242-1250
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2139678747
- Cited by
- 592
- References
- 43
- FWCI
- 27.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.